Iterum Therapeutics - ITRM Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ITRM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ITRM, but not buy additional shares or sell existing shares.
View ITRM analyst ratings or view top-rated stocks.

Iterum Therapeutics' stock was trading at $0.84 on January 1st, 2023. Since then, ITRM shares have increased by 11.9% and is now trading at $0.94.
View the best growth stocks for 2023 here.

Iterum Therapeutics saw a drop in short interest in March. As of March 15th, there was short interest totaling 154,400 shares, a drop of 15.5% from the February 28th total of 182,700 shares. Based on an average trading volume of 101,600 shares, the short-interest ratio is currently 1.5 days. Currently, 1.2% of the shares of the company are short sold.
View Iterum Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, May 12th 2023.
View our ITRM earnings forecast.

Iterum Therapeutics plc (NASDAQ:ITRM) posted its quarterly earnings data on Friday, November, 12th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.80 by $1.50. During the same quarter last year, the business posted ($5.10) EPS.

Shares of Iterum Therapeutics reverse split on Thursday, August 18th 2022. The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Iterum Therapeutics investors own include Aeglea BioTherapeutics (AGLE), Viking Therapeutics (VKTX), Acasti Pharma (ACST), Axsome Therapeutics (AXSM), Innovate Biopharmaceuticals (INNT), OPKO Health (OPK), VYNE Therapeutics (VYNE), Fulcrum Therapeutics (FULC), Ocugen (OCGN).

(ITRM) raised $80 million in an initial public offering (IPO) on Friday, May 25th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

Iterum Therapeutics trades on the NASDAQ under the ticker symbol "ITRM."

Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ITRM stock can currently be purchased for approximately $0.94.

Iterum Therapeutics (NASDAQ:ITRM) has a market capitalization of $11.95 million. The company earns $-44,430,000.00 in net income (profit) each year or ($3.6896) on an earnings per share basis.

Iterum Therapeutics' mailing address is BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2. The official website for the company is www.iterumtx.com. The company can be reached via phone at (531) 669-4820 or via email at ir@iterumtx.com.